New PCAOB Audit Reporting Standards Set for International Accounting
The PCAOB, otherwise known as the US Public Company Accounting Oversight Board, is shaking things up in the audit industry!...
Securities & Exchange
New Audit Reporting Standards Set by PCAOB
The Public Company Accounting Oversight Board (PCAOB) has recently introduced new audit reporting standards aimed at enhancing transparency and ensuring...
Merck ZENITH Trial Phase 3: Evaluation of WINREVAIR™ (sotatercept-csrk)
Merck, also recognized as MSD outside of the United States and Canada, just shared exciting news about their Phase 3...
Merck’s ZENITH Trial: Phase 3 Evaluation of WINREVAIR (sotatercept-csrk)
Merck recently shared some exciting news about their Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept-csrk) for the treatment of patients...
UPS and SEC: The Potential Dangers of Goodwill Treatment
Let's take a closer look at a recent announcement from the Securities and Exchange Commission (SEC) that came out last...
UPS and the SEC: Risks of Goodwill Treatment
Let's dive into a recent statement from the Securities and Exchange Commission (SEC) that was released last Friday, November 22nd....
Citius Pharmaceuticals Reports FDA Type C Meeting for Phase 3 Mino Study
Citius Pharmaceuticals, a biopharmaceutical company focused on critical care products, recently had a successful Type C meeting with the U.S....
Citius Pharmaceuticals Update on FDA Type C Meeting for Phase 3 Minocycline Study
Citius Pharmaceuticals recently shared exciting news about a successful meeting with the FDA. The company, devoted to developing and bringing...
ConocoPhillips Company Exchange Offers for Debt Securities and Consent
ConocoPhillips has some big news to share! In light of their recent acquisition of Marathon Oil Corporation, they're offering a...
ConocoPhillips Company Debt Exchange Offers and Consent Announcement
ConocoPhillips Company has some big news to share! In light of their recent acquisition of Marathon Oil Corporation, they are...
CytoDyn Appoints Dr. Richard Pestell as Lead Oncology Consultant
CytoDyn, a biotech company working on leronlimab, a CCR5 antagonist with the potential for diverse therapeutic applications, has appointed Dr....
CytoDyn Names Richard Pestell, M.D., Ph.D. as Lead Oncology Consultant
CytoDyn, a biotechnology company known for developing leronlimab, a promising CCR5 antagonist drug for various therapeutic uses, recently appointed Dr....